Dexcom is in seventh heaven: A year after its initial FDA submission, the diabetes tech maker has finally gotten the green light to begin rolling out its latest continuous glucose monitor system in ...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada ...

One of medtech’s most anticipated devices has won approval in Europe. Dexcom has received CE mark for its long-awaited G7 Continuous Glucose Monitoring System for people with diabetes in age two years ...

Tandem Diabetes Care, Inc.’s TNDM Mobi insulin pump with Control-IQ technology is now fully compatible with both Dexcom’s DXCM G7 and G6 Continuous Glucose Monitoring (“CGM”) Systems. The world’s ...

After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With ...

Dexcom announced last week that its G7 continuous glucose monitoring system has received FDA clearance. The latest model of its CGM, which can be used by people with all types of diabetes ages 2 and ...

The device is similar to existing prescription CGMs. Users pair the wearable sensor with an application, put it on their arm and receive a continuous stream of glucose data on their smartphone or ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

One of the most anticipated devices in medtech has finally won a nod from FDA. Dexcom closes out 2022 with clearance for the G7 Continuous Glucose Monitor after facing a few delays. The device is ...